About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Active Drug Surveillance Program of Ferriprox Use | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01838291

Active Drug Surveillance Program of Ferriprox Use

Observational, open label, prospective, multi-center, post-marketing drug surveillance program.

Lead sponsor: ApoPharma•14 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

ApoPharma

A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who started Ferriprox therapy less than one month or are to initiate Ferriprox therapy at the time of enrolment into the program.

Exclusion Criteria

•Patients treated with Ferriprox for more than one month prior to enrolment.

Related studies

WITHDRAWNPhase 2

Treatment of Iron Overload Requiring Chelation Therapy

NCT01927913 · Transfusional Iron Overload, Iron Overload, and more

COMPLETEDPhase 1

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820 · β-thalassemia, Transfusional Iron Overload

COMPLETEDPhase 2

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

NCT00390858 · Transfusional Iron Overload, β-thalassemia Major, and more

COMPLETEDPhase 2

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

NCT01044186 · Transfusional Iron Overload

COMPLETEDPhase 3

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

NCT00171210 · Transfusional Iron Overload in β-thalassemia

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 24, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment294

Start dateJun 2010

Last updatedApr 24, 2013

Condition

Transfusional Iron Overload

Locations shown

Thalassemia Center of North Cyprus Turkish Republic (KKTC)

Nicosia

Hematology Unit, Mansoura University Children Hospital

Al Mansurah

Hematology Unit, El-Shatby Children Hospital, Alexandria University

Alexandria

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 24, 2013Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions